DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION							
DISTRICT OFFICE A	ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION					
U.S. Food and Drug Administration			11/7-9,13-16,20/2017	3			
555 Winderley Place Suite 200 Maitland, FL 32751			FEI NUMBER				
Industry Information: www fda.gov/oc/industry			3013918415				
	OF INDIVIDUAL TO WHOM REPORT IS ISSUED						
TO. Veronica	Γaran, President and Owner						
FIRM NAME STREET ADDRESS							
Pharmacy Doctors Enterprises dba Zion Clinical Pharmacy 205 East Hallandale E			each Blvd.				
CITY, STATE AND ZIP CODE TYPE OF ESTABLISHMENT			NSPECTED				
Hallandale Beach, FL 33009 Producer of Sterile an			l Non-Sterile Drugs				
OBSERVATIONS; A OBSERVATION, OF OBJECTION OR AC YOU HAVE ANY QU	LISTS OBSERVATIONS MADE BY THE FDA REPRESENTAT IND DO NOT REPRESENT A FINAL AGENCY DETERMINATIO R HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRICTION WITH THE FDA REPRESENTATIVE(S) DURING THE INJESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER CTION OF YOUR FIRM (I) (WE) OBSERVED:	ON REGARDING YOUR COMPLIA ECTIVE ACTION IN RESPONS INSPECTION OR SUBMIT THIS I	ANCE. IF YOU HAVE AN OBJETO AN OBSERVATION, Y	JECTION REGARDING AN YOU MAY DISCUSS THE			
Observation 1:							
Highly potent drugs such as buprenorphine HCl and hazardous drugs such as human chorionic gonadotropin (HCG) were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.							
Specifically,							
vials, beakers adjacent to th	f potential cross contamination include the s, and utensils are cleaned which is a single se ISO 7 buffer room door. The buffer room culating air flow.	e basin hand wash sinl	k located in the ISO				
			Ad	d Continuation Page			
he the sufferior of	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE	(Print or Type)	DATE ISSUED			
SEE REVERSE OF THIS PAGE	Joanne E. King - S Digitally signed by Asane E King S Disc-US Government dou-HES ou-IDA ou-Phospie cn-Joanne E King S 09 2342 102002000 100 11-1300174867 Date: 2017 11 20 15:35 \$1 65 00	Joanne E. King, Investigator		11/20/2017			

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION							
DISTRICT OFFICE A	ADDRESS AND PHONE NUMBER		DATE(S) OF INSPECTION				
U.S. Food and Drug Administration 555 Winderley Place Suite 200 Maitland, FL 32751			11/7-9,13-16,20/2017				
			FEI NUMBER				
Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED			3013918415				
TO: Veronica I	Taran, President and Owner	STREET ADDRESS					
10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		205 East Hallandale B	Parah Dhrd				
CITY, STATE AND Z							
Hallandale Beac		Producer of Sterile and Non-Sterile Drugs					
C. Sporicidal agents are not used in your facility's cleanrooms and/or ISO 5 area within the (b) (4) D. The facility is also designed and/or operated in a way that permits poor flow of personnel or materials in that the (b) (4) , and non-sterile processing components are all stored in the ISO 7 ante-room. The presence of this equipment and operations of use may increase the presence of dust particles, increase the room humidity as well as elevate the room temperature. Higher particle counts surrounded by moist warm air may increase the rooms bacterial and fungal bio-burden.							
These sterile and non-sterile human and animal drug preparations include the following: • buprenorphine HCL 0.3mg/ml for injection 30 ml multi-dose vial (veterinary drug) lot BUV030526 • tadalafil/arginine 20/300 mg capsules lot TAC201530 • metronidazole 5% ointment lot ABMO • Z4 dental gel (lidocaine HCl 10%, prilocaine HCl 10%, tetracaine HCL 4%, phenylephrine 2%) lot Z4D003524 • Sermorelin+GHRP2+GHRP6 100/100/200 mcg troches lot SEM620684 • Nifedipine 0.3% lidocaine 1.5% ointment lot ABNFO • No pain gel lidocaine HCl 0.1g, tetracaine HCL 0.04g, phenylephrine HCl 0.2g, prilocaine 0.1g lot Z4D003525 • HCG (human chorionic gonadotropin) troches 250 IU Lot HCGTR5058 Add Continuation Page							
	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE	E (Print or Type)	DATE ISSUED			
SEE REVERSE OF THIS PAGE		Joanne E. King, Investigator		11/20/2017			